1. Spain Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Almirall, S.A.

Almirall, S.A.

ALM.MC
Almirall, S.A.ES flagMadrid Stock Exchange
11.50
EUR
+0.10
- -
2.50BMarket Cap
Almirall, S.A.
ALM.MC
(Madrid Stock Exchange)

Recent

price

11.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
5.14
4.58
4.09
4.2
4.58
3.85
4.27
3.56
4.2
9.44
4.36
4.42
4.24
4.09
4.54
5.1
6.31
Revenue per Share
0.69
0.49
0.43
-0.19
2.51
0.74
0.42
-1.69
0.43
0.58
0.4
-0.22
0.02
-0.18
0.05
0.21
0.24
Basic EPS, GAAP
0.48
0.36
0.19
0.02
3.23
0.81
0.13
-0.35
-2.53
0.78
0.2
0.87
0.19
-0.3
- -
0.17
0.9
Free Cash Flow per Basic Share
0.32
0.28
0.01
- -
- -
0.2
0.18
0.18
0.13
0.13
0.01
0.06
0.06
0.01
0.02
0.12
- -
Dividend per Share
0.81
0.61
0.54
-0.07
2.62
0.85
0.54
-1.58
0.55
0.7
0.52
-0.1
0.13
-0.06
0.16
0.33
- -
Book Value per Share
0.96
1.34
1.65
-0.24
3.11
3.93
0.53
0.34
-1.36
-0.96
-0.12
0.29
0.51
0.9
1.08
1.27
1.21
Tangible Book Value per Share
172
172
179
179
179
179
179
179
180
181
185
187
204
219
217
217
218
Basic Weighted Avg Shares
882
787
732
752
819
689
764
639
757
1,711
807
827
863
895
986
1,108
1,375
Sales/Revenue/Turnover
17.6
12.35
7.71
2.16
69
18.09
12.69
2.53
14.74
59.43
13.59
13.46
7.97
4.61
4.74
6.02
6.8
Operating Margin (%)
62
63
68
69
85
74
100
104
90
129
123
120
121
124
139
151
152
Depreciation Expense
119
84
76
-34
448
132
75
-304
78
106
74
-41
4
-38
10
46
52
Net Income, GAAP
0.48
- -
- -
- -
6.96
23.64
18.52
- -
- -
17.44
6.26
- -
86.2
- -
61.71
38.01
36.91
Effective Tax Rate (%)
13.44
10.7
10.42
-4.49
54.75
19.13
9.87
-47.54
10.26
6.19
9.2
-4.94
0.5
-4.3
1.03
4.17
3.81
Profit Margin (%)
166
45
61
-63
746
846
367
167
170
160
15
218
278
368
388
363
397
Working Capital
149
17
15
254
332
333
331
263
532
492
243
378
387
386
391
325
285
LT Debt
819
855
924
888
1,340
1,463
1,520
1,134
1,192
1,280
1,303
1,286
1,319
1,463
1,488
1,487
1,507
Total Equity
14.25
- -
- -
- -
36.19
5.39
4.27
- -
- -
47.43
5.68
- -
0.55
- -
0.94
2.18
3.24
Return on Invested Capital (%)
38.61
- -
- -
- -
82.87
20.11
16.16
- -
- -
17.57
13.85
- -
1.32
- -
3.19
11.95
21.04
Return on Capital (%)
171.22
69.38
75.97
- -
- -
42.4
60.67
- -
- -
93.98
66.77
- -
- -
- -
- -
85.72
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
18
- -
LT Borrowings
337
290
285
LT Finance Leases
- -
35
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
215
215
215
Market Capitalization
2,757
2,787
2,648

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
777
714
699
Cash, Cash Equivalents & STI
377
339
311
Accounts Receivable, Net
160
145
162
Inventories
189
178
176
Total Current Liabilities
305
351
302
Payables & Accruals
- -
- -
- -
ST Debt
- -
18
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.67%
2.77%
-0.08%
Free Cash Flow
-583.13%
-1,158.33%
-5,695.03%
Net Income, GAAP
-170.02%
-207.15%
354.85%
Sales/Revenue/Turnover
11.92%
6.61%
12.41%
Total Cash Common Dividend
- -
220.38%
696.75%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
249
248
230
489
986
2025
286
274
260
548
1,108
2026
292
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
- -
- -
-0.02
0.05
2025
0.1
- -
- -
0.09
0.21
2026
0.07
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.02
2025
- -
- -
- -
- -
0.12
2026
- -
- -
- -
- -
- -
Similar Companies
CKD Bio Corp. (063160.KS)
FDC Limited (FDC.NS)
Biofrontera AG (B8F.DE)
Modalis Therapeutics Corporation (4883.T)
BioHarvest Sciences Inc. (BHSC.CN)
Cannabis Global Inc. (CBGL)
Business
Almirall, S.A. Almirall, S.A. is a global biopharmaceutical company focused on medical dermatology that develops, manufactures and commercializes prescription treatments for skin diseases including psoriasis, atopic dermatitis, actinic keratosis, acne, rosacea, onychomycosis and androgenic alopecia; key products comprise Skilarence for psoriasis, Ilumetri, Wynzora (growing 32.4% year-over-year), Klisyri (growing 22.6% year-over-year), Ebglyss, Aczone, Tazorac, Seysara and Cordran Tape. Founded in 1944 and headquartered in Barcelona, Spain, the company operates through 14 affiliates across Europe and the US, with presence in over 100 countries, supported by R&D centers, chemical and pharmaceutical plants in Spain and Germany, and a workforce exceeding 2,000 employees representing 40 nationalities. Almirall, S.A. invests 12.6% of net sales in R&D, pursuing external innovation including expanded collaboration with Simcere on multispecific antibodies for immunodermatology and autoimmune kidney diseases, partnerships with Novo Nordisk and Eloxx Pharmaceuticals, initiation of a phase II study for anti-IL-1RAP mAb, plans for three additional proof-of-concept studies, a Microsoft collaboration for generative AI capabilities, and robust 2025 performance with 12.8% net sales growth in the first nine months driven by dermatology portfolio strength.